Antiplatelet medications divide into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban, eptifibatide are only available as parenteral agents and used in acute phases of acute coronary syndrome (ACS).
Following are a few indications of antiplatelet medications:
Aspirin is the most commonly used oral antiplatelet drug. It works by irreversibly inhibiting the cyclooxygenase enzyme (COX) activity in the prostaglandin synthesis pathway (PGH2). This prostaglandin is a precursor of thromboxane A2 and PGI2. Thromboxane A2 works by inducing platelet aggregation and vasoconstriction, and COX-1 inhibits its production while PGI2 works by inhibiting platelet aggregation and induces vasodilation and is inhibited by COX-2. Low dose aspirin (75 mg - 150 mg) can induce complete or near-complete inhibition of COX-1, thus inhibiting the production of TXA2 while larger doses are required to inhibit COX-2.
Oral thienopyridines selectively inhibit adenosine diphosphate induced (ADP-induced) platelet aggregation. These drugs convert to an active drug with the help of the hepatic CYP450 system that inhibits the platelet P2Y12 receptor. Prasugrel is the most potent of all three drugs, has a rapid onset of action, and is superior to clopidogrel in patients undergoing coronary stenting. Ticlopidine has fallen out of favor because of bone marrow toxicity. Cangrelor is a new intravenous, reversible P2Y12 receptor antagonist and has a rapid onset of action. It achieves a significant level of platelet inhibition compared with clopidogrel.
Glycoprotein platelet inhibitors work by inhibiting glycoprotein IIb/IIIa (GpIIb-IIIa) receptors on platelets, thus decreasing platelet aggregation and most commonly used in an acute form of ACS. These drugs are only available in an intravenous form and thus used as short-term therapy.
Dipyridamole has antiplatelet and vasodilating properties and inhibits platelet cyclic nucleotide phosphodiesterase. This enzyme is responsible for the degradation of adenosine monophosphate (AMP) to 5'AMP, which increases intra-platelet cyclic AMP accumulation and inhibits platelet aggregation. It also blocks the uptake of adenosine by the platelets, which also increase cyclic AMP.
Cilostazol is also reported to have vasodilatory, antiplatelet properties, and antiproliferative effects. It also reduces smooth muscle cell hyperproliferation and intimal hyperplasia after an injury to the endothelium.
Antiplatelet agent administration can be via oral, rectal, or intravenous routes. Oral medications include aspirin, clopidogrel, ticagrelor, cilostazol, and dipyridamole. Intravenous drugs include GpII-IIIA inhibitors and can be used for a short period, most commonly during acute coronary syndromes before or during PCI. Aspirin is available as a rectal suppository if the patient cannot take the drug orally.
Following are the most common adverse effects associated with antiplatelet medications:
Headache, nausea, diarrhea, pain, infection, upper respiratory symptoms, palpitations, arrhythmias, and peripheral edema are the most common side effects associated with cilostazol.
Most common contraindications of antiplatelet agents are as follows:
Before starting antiplatelet agents, the patient should undergo assessment for bleeding risk. Advanced age, female gender, and impaired renal function are important factors to consider. The patient should be aware of the risks, benefits, and alternatives of antiplatelet agents. Monitoring is generally not required for antiplatelet medications; however, if bleeding is present, bleeding time will be useful to determine if a platelet transfusion is needed or if the medication requires discontinuation. In life-threatening bleeding such as massive upper gastrointestinal bleed, the clinician should stop the drug as soon as possible. If the antiplatelet is an essential therapy, such as in post-coronary stenting patients, the medications should be resumed as quickly as safely possible.
The use of concomitant anticoagulant should be minimized as much as possible as it will increase the risk of bleeding by many times. Discontinuance of clopidogrel and ticagrelor should be at least five days and prasugrel at least seven days before major cardiac or non-cardiac surgery.
Aspirin is the most commonly used of all antiplatelet drugs, so accidental intake is common. The effect can be life-threatening if taken over 150 mg/kg of the body weight. Supportive measure to decrease the absorption of the drug is achievable by using activated charcoal but only if administered within 4 hours of ingestion. The patient will need monitoring for signs and symptoms of bleeding and development of metabolic derangements, such as acidosis. If acidosis develops, immediate dialysis is indicated.
There is no antidote available for most of these drugs; however, a monoclonal antibody against ticagrelor is in development, but it is not commercially available as yet.
Antiplatelet drug therapy requires an interprofessional team approach, including clinicians, specialty-trained nurses, and pharmacists, all collaborating as an interprofessional team to achieve optimal patient results.
The choice of an antiplatelet agent depends on the clinical situation. Because of the availability of a large number of antiplatelet agents, the ordering/prescribing clinician should consult with a specialized pharmacist. When prescribing these agents, the pharmacist should review the patient's medication list as well as past diagnoses to determine if specific agents are recommended or contraindicated. Communication between the clinical provider and the pharmacists is essential to minimize adverse outcomes for patients when using these drugs. A cardiac pharmacist can offer direction regarding agent selection, drug-drug interactions, dose verification, and overall medication reconciliation for high-risk patients.
The role of the cardiac nurse administering these medications in the acute setting involves monitoring for any acute adverse symptoms and patient education in regards to the same. Prompt communication by astute nursing staff of an adverse reaction or a complication can significantly reduce patient morbidity and mortality.
Nurses are often the first healthcare provider to verify the therapeutic effectiveness of these agents and to monitor for adverse effects. This role becomes crucial in patients receiving dual antiplatelet therapy, as is often the case for the prevention of stent thrombosis or after an ACS event. The specialty-trained nurse not only educates the patient on possible complications but also regarding the indications for the prescribed therapy as well as the need for compliance with the treatment regimen. The nurse should communicate with the clinical provider and the pharmacist if noting any adverse reaction or if there is a concern for patient compliance with therapy so that alternative therapies can be considered. An interprofessional approach, with a multifaceted and targetted approach to treatment, is necessary to improve patient outcomes with antiplatelet medications. [Level 5]
|||Eikelboom JW,Hirsh J,Spencer FA,Baglin TP,Weitz JI, Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; [PubMed PMID: 22315278]|
|||Krötz F,Sohn HY,Klauss V, Antiplatelet drugs in cardiological practice: established strategies and new developments. Vascular health and risk management. 2008; [PubMed PMID: 18827913]|
|||Hashemzadeh M,Furukawa M,Goldsberry S,Movahed MR, Chemical structures and mode of action of intravenous glycoprotein IIb/IIIa receptor blockers: A review. Experimental and clinical cardiology. 2008 Winter; [PubMed PMID: 19343166]|
|||Warner TD,Nylander S,Whatling C, Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. British journal of clinical pharmacology. 2011 Oct; [PubMed PMID: 21320154]|
|||Kubica J,Kozinski M,Navarese EP,Tantry U,Kubica A,Siller-Matula JM,Jeong YH,Fabiszak T,Andruszkiewicz A,Gurbel PA, Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current medical research and opinion. 2014 May; [PubMed PMID: 24393016]|
|||Harker LA,Kadatz RA, Mechanism of action of dipyridamole. Thrombosis research. Supplement. 1983; [PubMed PMID: 6356465]|
|||Goto S, Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atherosclerosis. Supplements. 2005 Dec 15; [PubMed PMID: 16275169]|
|||Kalyanasundaram A,Lincoff AM, Managing adverse effects and drug-drug interactions of antiplatelet agents. Nature reviews. Cardiology. 2011 Sep 13; [PubMed PMID: 21912415]|
|||Barnes GD,Stanislawski MA,Liu W,Barón AE,Armstrong EJ,Ho PM,Klein A,Maddox TM,Nallamothu BK,Rumsfeld JS,Tsai TT,Bradley SM, Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. Circulation. Cardiovascular quality and outcomes. 2016 Jul; [PubMed PMID: 27245070]|
|||Dargan PI,Wallace CI,Jones AL, An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose. Emergency medicine journal : EMJ. 2002 May; [PubMed PMID: 11971828]|